Mônica R. Gadelha

ORCID: 0000-0002-9250-3558
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pituitary Gland Disorders and Treatments
  • Growth Hormone and Insulin-like Growth Factors
  • Adrenal and Paraganglionic Tumors
  • Neuroendocrine Tumor Research Advances
  • Glioma Diagnosis and Treatment
  • Adrenal Hormones and Disorders
  • Ophthalmology and Eye Disorders
  • Myasthenia Gravis and Thymoma
  • Cancer, Hypoxia, and Metabolism
  • Meningioma and schwannoma management
  • Neuroblastoma Research and Treatments
  • Hormonal Regulation and Hypertension
  • TGF-β signaling in diseases
  • Hedgehog Signaling Pathway Studies
  • Neurofibromatosis and Schwannoma Cases
  • Antioxidant Activity and Oxidative Stress
  • Vascular Malformations and Hemangiomas
  • Sexual Differentiation and Disorders
  • Connective tissue disorders research
  • Scoliosis diagnosis and treatment
  • COVID-19 Clinical Research Studies
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cerebrospinal fluid and hydrocephalus
  • Chromatin Remodeling and Cancer
  • MicroRNA in disease regulation

Universidade Federal do Rio de Janeiro
2016-2025

Hospital Universitário Clementino Fraga Filho
2016-2025

Instituto Estadual do Cérebro Paulo Niemeyer
2016-2025

Novo Nordisk (United Kingdom)
2024

Cedars-Sinai Medical Center
2024

Ipsen (Spain)
2024

Cambia
2024

Recordati (Spain)
2024

Takeda (Italy)
2024

Secretaria da Saúde
2023

Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many do not achieve biochemical control.Our objective was to demonstrate superiority of pasireotide LAR over medically naive acromegaly.We conducted a prospective, randomized, double-blind study at 84 sites 27 countries.A total 358 acromegaly (GH >5 μg/L or GH nadir ≥1 after an oral glucose tolerance...

10.1210/jc.2013-2480 article EN cc-by-nc The Journal of Clinical Endocrinology & Metabolism 2014-01-14

Context: Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene familial isolated pituitary adenomas (FIPA). It is not clear, however, how this molecular chaperone involved tumorigenesis. Objective: AIP sequence changes and expression were studied FIPA sporadic adenomas. The function of normal mutated molecules was on cell proliferation protein-protein interaction. Cellular ultrastructural localization determined cells. Patients: Twenty-six kindreds 85...

10.1210/jc.2007-2611 article EN The Journal of Clinical Endocrinology & Metabolism 2008-04-02

Abstract Objective The aim of the Acromegaly Consensus Group was to revise and update consensus on diagnosis treatment acromegaly comorbidities last published in 2013. Participants Group, convened by 11 Steering Committee members, consisted 45 experts medical surgical management acromegaly. authors received no corporate funding or remuneration. Evidence This evidence-based developed using Grading Recommendations, Assessment, Development, Evaluation (GRADE) system describe both strength...

10.1210/clinem/dgz096 article EN The Journal of Clinical Endocrinology & Metabolism 2019-10-13

We have recently reported somatic mutations in the ubiquitin-specific protease USP8 gene a small series of adenomas patients with Cushing's disease.To determine prevalence and genotype-phenotype correlation large diagnosed disease.We performed retrospective, multicentric, genetic analysis 134 functioning 11 silent corticotroph using Sanger sequencing. Biochemical clinical features were collected examined within context mutational status USP8, new characterized by functional studies.A total...

10.1210/jc.2015-1453 article EN The Journal of Clinical Endocrinology & Metabolism 2015-05-05

Abstract Purpose The 14th Acromegaly Consensus Conference was convened to consider biochemical criteria for acromegaly diagnosis and evaluation of therapeutic efficacy. Methods Fifty-six experts from 16 countries reviewed discussed current evidence focused on assays; the role imaging, pathology, clinical assessments; consequences diagnostic delay; remission recommendations follow up; value assessment monitoring in defining disease progression, selecting appropriate treatments, maximizing...

10.1007/s11102-023-01360-1 article EN cc-by Pituitary 2023-11-03

Objective : It is believed that the variable effectiveness of somatostatin analogs in post-surgical management somatotropinomas and non-functioning pituitary adenomas (NFPA) may be due part to expression receptor isoforms (SSTR1–5), within between tumor types. Design methods Quantitative real-time RT-PCR was used compare absolute mRNA copy numbers for all five SSTR 23 19 NFPA. Results Somatostatin subtype 5 present at highest level somatotropinomas, followed by SSTR2>SSTR3≫SSTR1⋙SSTR4. In...

10.1530/eje.1.02313 article EN European Journal of Endocrinology 2007-01-01

Objective To determine whether the somatostatin receptor subtype (SSTR) expression profile correlates with hormonal and tumor volume responses to postsurgical octreotide long acting repeatable (OCT LAR) treatment. Design methods Quantitative real-time RT-PCR was used evaluate absolute mRNA copy numbers for all five SSTR subtypes in 22 somatotropinomas. Response OCT LAR studied by hormone levels (GH IGF-I) (sella turcica magnetic resonance imaging). Results SSTR5 present at highest level...

10.1530/eje-07-0562 article EN European Journal of Endocrinology 2008-02-25
Laura C. Hernández‐Ramírez Plamena Gabrovska Judit Dénes Karen Stals Giampaolo Trivellin and 95 more Daniel Tilley Francesco Ferraù Jane Evanson Sian Ellard Ashley Grossman Federico Roncaroli Mônica R. Gadelha Márta Korbonits Amar Agha Scott Akker Elena Daniela Aflorei Sándor Alföldi Wiebke Arlt Brew Atkinson Anna Aulinas-Masó Simon Aylwin Philippe Backeljauw Corin Badiu Stephanie Baldeweg Gul Bano Ariel Barkan Julian Barwell Carmen Bernal-González G. M. Besser John S. Bevan Joanne Blair Pierre Bouloux Lisa Bradley Michael Buchfelder Mehtap Çakır Natalie Canham Paul Carroll Harvinder Chahal Tim Cheetham F. Chentli Richard N. Clayton Mark L. Cohen Trevor Cole Hamish Courtney Elizabeth Crowne Daniel J. Cuthbertson Jacob Dal Nadezhda Dalantaeva Christina Daousi Ken Darzy Mehul Dattani Justin H. Davies J.R. Davis Margaret de Castro Laura De Marinis William Drake Pinaki Dutta Larisa Dzeranova Britt Edén Engström Rosalind A. Eeles Maria Elfving Marianne S. Elston Louise Emmerson Naomi Fersht Simona Fica Stefan Fischli Daniel Flanagan Maria Fleseriu Pamela U. Freda Theodore C. Friedman Lawrence A. Frohman Patricia Gallego Evelien Gevers Edit Gláz James A. Goldman Anthony P. Goldstone Miklós Góth Lynn Greenhalgh Joan Grieve Mirtha Guitelman Alper Gürlek Mark Gurnell Katalin Horváth Trevor A. Howlett Charlotte Höybye Steven Hunter Donato Iacovazzo Péter Igaz Warrick J. Inder Takeo Iwata Louise Izatt Sujatha Jagadeesh Gregory Kaltsas Felicity Kaplan Niki Karavitaki Darko Kaštelan Michelle L. Katz Tara Kearney Bernard Khoo Cathy Kiraly‐Borri

Familial isolated pituitary adenoma (FIPA) due to aryl hydrocarbon receptor interacting protein (AIP) gene mutations is an autosomal dominant disease with incomplete penetrance. Clinical screening of apparently unaffected AIP mutation (AIPmut) carriers could identify previously unrecognized disease. To determine the mutational status FIPA and young patients, analyzing their clinical characteristics, perform AIPmut carrier family members. This was observational, longitudinal study conducted...

10.1210/jc.2015-1869 article EN cc-by The Journal of Clinical Endocrinology & Metabolism 2015-07-17

Hyperprolactinemia might be related to weight gain, metabolic syndrome (MS), and insulin resistance (IR). Treatment with dopamine agonist (DA) has been shown reduce body improve parameters. The objectives of this study were determine the prevalence obesity, overweight, MS, IR in patients prolactinoma before after therapy DA evaluate relation between prolactin (PRL), weight, fat distribution, leptin levels, IR, lipid profile treatment. In addition, we investigated correlation reduction PRL...

10.1038/oby.2010.150 article EN Obesity 2010-06-17

Dopamine receptor (DR) and somatostatin subtype expression in pituitary adenomas may predict the response to postsurgical therapies.Our objectives were assess compare mRNA levels of DR1-5 receptors 1-5 normal pituitaries (NPs), nonfunctioning (NFPAs), somatotropinomas. In addition, we determined whether level DR correlates with vivo octreotide-LAR acromegalic patients.Eight NPs, 30 NFPAs, 39 somatotropinomas analyzed for by real-time RT-PCR. The DR2 short variant was estimated as long/DR2...

10.1210/jc.2008-1826 article EN The Journal of Clinical Endocrinology & Metabolism 2009-03-18
Coming Soon ...